2026-11-13. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with this event.
Teva President and CEO Richard Francis joins 'Mad Money' host Jim Cramer to talk its first R&D day, where it is seeing growth opportunities, its individual offerings, and more.
Teva Pharmaceutical Industries Ltd (TEVA) lifted full-year revenue and free cash flow guidance on the strength of AUSTEDO, AJOVY, and UZEDY, even as total revenue slipped 2% and generics fell 16%.
Teva Pharmaceutical Industries reported Q3 2026 sales of US$4.4b with earnings that topped some analyst expectations, while branded drugs AUSTEDO, AJOVY, UZEDY and new schizophrenia therapy WELTRUZA together produced strong revenue momentum and led management to raise the 2026 outlook for these key products. The new U.S. biosimilars agreement with Samsung Bioepis on infliximab-abda and etanercept-ykro adds another revenue pillar alongside Teva's higher margin central nervous system...
Teva Pharmaceutical Industries (NYSE:TEVA) ended its Phase 2 TOPAS-MSA trial of emrusolmin after an interim futility analysis showed insufficient efficacy. Management reported strong sales for UZEDY, its long acting injectable for schizophrenia, and raised the product's revenue outlook. No safety concerns were identified for emrusolmin in the discontinued study, according to the company’s update. Teva’s halt of emrusolmin and upgraded UZEDY outlook only capture part of how its central...
Teva Pharmaceutical (TEVA) stock is in focus as the company gains U.S. rights to two biosimilars owned by Samsung Bioepis. Read more here.
Teva stock advanced early Tuesday on better-than-expected third-quarter metrics and a raised outlook for 2026.
Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals. Read more on TEVA here.
This is the newest page. Registered accounts read further back.